107415-26-9

Basic information

• Product Name: N-(7-chloro-4-quinolinyl)-N-[2-(dimethylamino)ethyl]amine
• Synonyms: N-(7-chloro-4-quinolinyl)-N-[2-(dimethylamino)ethyl]amine
• CAS NO: 107415-26-9
• Molecular Formula: C₁₃H₁₆ClN₃
• Molecular Weight: 249.73924
• Mol File: 107415-26-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(7-chloro-4-quinolinyl)-N-[2-(dimethylamino)ethyl]amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(7-chloro-4-quinolinyl)-N-[2-(dimethylamino)ethyl]amine(107415-26-9)
• EPA Substance Registry System: N-(7-chloro-4-quinolinyl)-N-[2-(dimethylamino)ethyl]amine(107415-26-9)

Safety Data

• Hazardous Substances Data: 107415-26-9(Hazardous Substances Data)

Upstream product

• 86-98-6 4,7-dichloroquinoline 
• 108-00-9 N,N-dimethylethylenediamine 

Relevant articles and documents

Structure-function correlation of chloroquine and analogues as transgene expression enhancers in nonviral gene delivery

To understand how chloroquine (CQ) enhances transgene expression in polycation-based, nonviral gene delivery systems, a number of CQ analogues with variations in the aliphatic amino side chain or in the aromatic ring are synthesized and investigated. Our studies indicate that the aliphatic amino moiety of CQ is essential to provide increased gene expression. Further, the enhancements are more dramatically affected by changes to the aromatic ring and are positively correlated to the strength of intercalation between DNA and the CQ analogues. Quinacrine (QC), a CQ analogue with a fused acridinyl structure that can strongly intercalate DNA, enhances transfection similarly to CQ at a concentration 10 times lower, while N4-(4-pyridinyl)-N 1,N1-diethyl-1,4-pentanediamine (CP), a CQ analogue that has a weakly intercalating pyridinyl ring, shows no effect on gene expression. Subtle change on the 7-substituent of the chloroquine aromatic structure can also greatly affect the ability of the CQ analogues to enhance transgene expression. Transfection in the presence of N4-(7-trifluoromethyl-4- quinolinyl)-N1,N1-diethyl-1,4-pentanediamin e (CQ7a) shows expression efficiency 10 times higher than in the presence of CQ at-same concentration, while transfection in the presence of N4-(4- quinolinyl)-N1,N1-diethyl-1,4-pentanediamine (CQ7b) does not reveal any enhancing effects on expression. Through a number of comparative studies with CQ and its analogues, we conclude that there are at least three mechanistic features of CQ that lead to the enhancement in gene expression: (i) pH buffering in endocytic vesicles, (ii) displacement of polycations from the nucleic acids in polyplexes, and (iii) alteration of the biophysical properties of the released nucleic acid.

Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation

The present invention relates to novel ophthalmic pharmaceutical compositions comprising an inflammation-treating amount of a 4-aminoquinoline compound, derivative, isomers, or chemical salts, and methods for using these compositions for the treatment of ocular inflammatory conditions by topical administration directly to the eye.